Enliven Therapeutics, Inc.
ELVN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001672619
In the last 90 days, Enliven Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 214 institutions reported holding it in 13F filings for Q2 2026, worth $4.06B in total; no superinvestor holds it.
13F holders, Q4 2022
Institutional positions in Enliven Therapeutics, Inc. as of Dec 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 36
- +6 vs. Q3 2022
- Shares held
- 18.3M
- +10.1M (+124.7%) vs. Q3 2022
- Total value
- $74.7M
- +$56.1M (+302.9%) vs. Q3 2022
- New holders
- 17
- 9 more added
- Sold out
- 11
- 8 more reduced
1 institution that held it in Q3 2022 haven't filed for Q4 2022 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ELVN on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 214 | $4.06B |
| Q1 2026 | 171 | $2.43B |
| Q4 2025 | 126 | $960.9M |
| Q3 2025 | 134 | $1.22B |
| Q2 2025 | 125 | $1.19B |
| Q1 2025 | 122 | $983.9M |
| Q4 2024 | 114 | $1.12B |
| Q3 2024 | 102 | $1.22B |
| Q2 2024 | 93 | $1.13B |
| Q1 2024 | 74 | $780.8M |
| Q4 2023 | 62 | $539.8M |
| Q3 2023 | 61 | $533.8M |
| Q2 2023 | 63 | $797.9M |
| Q1 2023 | 45 | $735.0M |
| Q4 2022 | 36 | $74.7M |
| Q3 2022 | 31 | $18.8M |
| Q2 2022 | 26 | $13.1M |
| Q1 2022 | 31 | $26.2M |
| Q4 2021 | 35 | $33.6M |
| Q3 2021 | 38 | $62.5M |
| Q2 2021 | 31 | $86.3M |
| Q1 2021 | 40 | $92.9M |
Institutions, Q4 2022
Shares, value and share of portfolio for each institution holding Enliven Therapeutics, Inc.; share changes are against Q3 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| OrbiMed Advisors LLC | 4,386,568 | $17.9M | 0.34% | 00.0% | Unchanged |
| Ra Capital Management, L.P. | 3,250,724 | $13.3M | 0.27% | +3,250,724 | New |
| BML Capital Management, LLC | 3,017,774 | $12.3M | 11.79% | +3,017,774 | New |
| Commodore Capital LP | 2,494,794 | $10.2M | 1.54% | +2,494,794 | New |
| Janus Henderson Group PLC | 928,706 | $3.77M | 0.00% | +928,706 | New |
| Woodline Partners LP | 866,405 | $3.54M | 0.05% | 00.0% | Unchanged |
| Citadel Advisors LLC | 776,785 | $3.18M | 0.00% | +681,443+714.7% | Added |
| Fairmount Funds Management LLC | 631,333 | $2.58M | 0.41% | +631,333 | New |
| Vanguard Group Inc | 441,213 | $1.80M | 0.00% | +137,058+45.1% | Added |
| Renaissance Technologies LLC | 213,800 | $874.0K | 0.00% | −115,524−35.1% | Reduced |
| JBF Capital, Inc. | 200,200 | $818.8K | 0.20% | −9,800−4.7% | Reduced |
| Diametric Capital, LP | 171,942 | $703.2K | 0.34% | +171,942 | New |
| Geode Capital Management, LLC | 137,726 | $563.0K | 0.00% | +32,651+31.1% | Added |
| BlackRock Inc. | 114,550 | $468.5K | 0.00% | +4,755+4.3% | Added |
| Bridgeway Capital Management, LLC | 99,700 | $407.8K | 0.01% | −26,800−21.2% | Reduced |
| FMR LLC | 95,345 | $390.0K | 0.00% | +95,345 | New |
| Prelude Capital Management, LLC | 61,142 | $250.1K | 0.02% | +61,142 | New |
| Morgan Stanley | 56,748 | $232.1K | 0.00% | −4,515−7.4% | Reduced |
| Bank of New York Mellon Corp | 52,027 | $212.8K | 0.00% | −392−0.7% | Reduced |
| Acuta Capital Partners, LLC | 44,503 | $182.0K | 0.11% | +44,503 | New |
| Marquette Asset Management, LLC | 37,745 | $154.4K | 0.05% | −13,822−26.8% | Reduced |
| State Street Corp | 37,698 | $154.2K | 0.00% | +16,500+77.8% | Added |
| Dimensional Fund Advisors LP | 35,891 | $147.0K | 0.00% | +7,626+27.0% | Added |
| Northern Trust Corp | 26,697 | $109.2K | 0.00% | +11,383+74.3% | Added |
| Two Sigma Advisers, LP | 25,700 | $105.1K | 0.00% | +25,700 | New |
| Great Valley Advisor Group, Inc. | 13,660 | $55.9K | 0.00% | −7,351−35.0% | Reduced |
| Cubist Systematic Strategies, LLC | 12,800 | $52.4K | 0.00% | +12,800 | New |
| Charles Schwab Investment Management Inc | 11,519 | $47.1K | 0.00% | +11,519 | New |
| Dorsey Wright & Associates | 5,500 | $22.5K | 0.01% | +5,500 | New |
| Tower Research Capital LLC (TRC) | 3,834 | $16.0K | 0.00% | +3,834 | New |
| Freedom Wealth Alliance, LLC | 3,100 | $12.7K | 0.02% | +3,100 | New |
| UBS Group AG | 2,845 | $11.6K | 0.00% | +2,845 | New |
| Federated Hermes, Inc. | 1,040 | $4.25K | 0.00% | −535−34.0% | Reduced |
| Royal Bank of Canada | 588 | $2.00K | 0.00% | +499+560.7% | Added |
| Bank of America Corp | 230 | $940 | 0.00% | +230 | New |
| Wells Fargo & Company | 97 | $397 | 0.00% | +3+3.2% | Added |
| Rock Springs Capital Management LP | 0 | $0 | 0.00% | −842,402−100.0% | Sold out |
| Caption Management, LLC | 0 | $0 | 0.00% | −170,000−100.0% | Sold out |
| Parallax Volatility Advisers, L.P. | 0 | $0 | 0.00% | −99,099−100.0% | Sold out |
| Group One Trading, L.P. | 0 | $0 | 0.00% | −92,994−100.0% | Sold out |
| MYDA Advisors LLC | 0 | $0 | 0.00% | −40,000−100.0% | Sold out |
| Anson Funds Management LP | 0 | $0 | 0.00% | −28,356−100.0% | Sold out |
| Tudor Investment Corp Et Al | 0 | $0 | 0.00% | −24,502−100.0% | Sold out |
| Rockefeller Capital Management L.P. | 0 | $0 | 0.00% | −18,000−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −15,792−100.0% | Sold out |
| AE Wealth Management LLC | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −9−100.0% | Sold out |
| Jefferies Group LLC | – | – | – | – | Not filed |